Phathom Pharmaceuticals Doubles Down on GI Focus with Strong Q2 Revenue Growth — Phathom Pharmaceuticals, Inc.

Event summary

Q2 2026 net revenues of $74.3 million, up 88% year-over-year and 27% quarter-over-quarter.
Operating expenses reduced by 33% year-over-year to $63.1 million.
VOQUEZNA® prescriptions reached 1.7 million total, with 325,000 in Q2 alone.
Phase 3 clinical trial for as-needed dosing of VOQUEZNA® in Non-Erosive GERD (NERD) to begin in Q4 2026.
Updated full-year 2026 revenue guidance lowered to $310–325 million from $320–345 million.

The big picture

Phathom Pharmaceuticals is executing a strategic pivot to focus on gastroenterology providers, reducing expenses by 33% year-over-year while nearly doubling quarterly revenue. The company's strong Q2 performance reflects its disciplined approach to cost management and commercial strategy, positioning VOQUEZNA® for potential blockbuster status in the GI market. The initiation of a Phase 3 trial for as-needed dosing in NERD could further expand the drug's market opportunity.

What we're watching

Commercial Strategy: How Phathom's shift to focus on gastroenterologists will impact VOQUEZNA's market penetration and revenue growth.
Pipeline Expansion: Whether the Phase 3 trial for as-needed dosing of VOQUEZNA® in NERD can successfully expand its market opportunity.
Financial Discipline: The pace at which Phathom can sustain cost reductions while maintaining revenue growth and operating profitability.